| Company/Division name | WuXi Biologics |
| Parent company | WuXi Pharma Tech |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 100 |
| Year reshoring announced: | 2020 |
| Country(ies) from which reshored: | China |
| City reshored to: | Cranbury |
| State(s) reshored to: | NJ |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | biopharma |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Government Incentives, Proximity to customers/market |
